NEWS

MultiplexDX NEWS

MultiplexDX Applies for Patent to Secure its Revolutionary Technology

MultiplexDX Receives €1,2 Million in Investments

MultiplexDX Wins Three Central European Startup Awards

MultiplexDX Receives €176 000 Grant from the Slovak Ministry of Education

MultiplexDX Selected to Join Health Hub Vienna, One of Europe’s Premiere Accelerators

MultiplexDX Wins Standard of Excellence Awards from the Web Marketing Association (WMA)

MultiplexDX Was Awarded Horizon 2020 Seal of Excellence by the European Commission

Hlavná cena a dve špeciálne ceny pre MultiplexDX v súťaži "Mladý inovatívny podnikateľ 2018”

MultiplexDX Is About to Close an Investment Round – Join Us

Multiplex DX Was Listed in the New Europe 100: Eastern Europe’s Emerging Technology Star

MultiplexDX Innovations. Unlocking the Full Potential of Personalized Cancer Diagnostics Through Multiplexed RNA-based Technologies.

MultiplexDX Launches FullRNALook - the Simplest and Most Robust RNA FISH on the Market

MultiplexDX Unveils Its Revolutionary Cancer Diagnostics Technology in a New Company Video

MultiplexDX Becomes an Overall Winner of the Prestigious Startup Awards 2016

PUBLICATIONS

Multiplexed miRNA Fluorescence In Situ Hybridization for Formalin-Fixed Paraffin-Embedded Tissues

Methods in Molecular Biology

Multicolor microRNA FISH effectively differentiates tumor types

The Journal of Clinical Investigation

Identification of Single-Base Mismatches in Duplex DNA by EPR Spectroscopy

Journal of the American Chemical Society

Folding of the cocaine aptamer studied by EPR and fluorescence spectroscopies using the bifunctional spectroscopic probe C

Nucleic Acids Research

Relative Orientation of Rigid Nitroxides by PELDOR: Beyond Distance Measurements in Nucleic Acids

Angewandte Chemie International Edition

Rigid spin-labeled nucleoside C¸ : a nonperturbing EPR probe of nucleic acid conformation

Nucleic Acids Research

Single base interrogation by a fluorescent nucleotide: each of the four DNA bases identified by fluorescence spectroscopy

Chemical Communications

Inside Cover

Angewandte Chemie International Edition

PRESS ABOUT MultiplexDX

Miliónová investícia do diagnostiky rakoviny. Slovenský MultiplexDX dostal injekciu

Polovica pacientov dostáva podľa vedca chemoterapiu zbytočne. Vyvíjajú test, ktorý má odstrániť chyby pri diagnostike

Ocenili mladých podnikateľov. Ich nápady prerazili i za hranicami

Pavol Čekan vyvíja špičkový test na liečbu rakoviny. Blíži sa na trh

Personalizovaná diagnostika nesmie byť iba nejakým „ROLLS-ROYCEOM“

Portrét Pavla Čekana

Diagnostic tests that lead to personalized treatment

Slovák, ktorý patrí k svetovej špičke. Vyvíja unikátne metódy na boj s rakovinou

Startup MultiplexDX vyvíja diagnostické testy na liečbu nádorov

Biochemik Pavol Čekan: “Najväčší úspech slovenskej vedy je, že ešte stále tu je.”

Unlocking the Full Potential of Personalized Medicine through Multiplexed RNA-Based Technologies

Liečme lepšie rakovinu

Startup Awards 2016 Winners

Lighting up micro RNAs

See all MultiplexDX clients